Evidence map›Paper›PMID 31255174›Full record

Trial reportArthritis research & therapy2019

Comparison of an interactive voice response system and smartphone application in the identification of gout flares.

Nada Elmagboul, Brian W Coburn, Jeffrey Foster, Amy Mudano, Joshua Melnick, Debra Bergman, Shuo Yang, David Redden, Lang Chen, Cooper Filby and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02855437 (Novel Methods for Ascertainment of Gout Flares -A Pilot Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02855437 nacompletednot on this map

Novel Methods for Ascertainment of Gout Flares -A Pilot Study

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2016 to 2018Enrolled44ConditionsGoutArmsIVR (Phone call), RheumPro (Smartphone application)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nada ElmagboulUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Brian W CoburnUniversity of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Jeffrey FosterUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Amy MudanoUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Joshua MelnickUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Debra BergmanUniversity of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Shuo YangUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
David ReddenUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Lang ChenUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Cooper FilbyUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Jeffrey R CurtisUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA.
Ted R MikulsUniversity of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Kenneth G SaagUniversity of Alabama at Birmingham, 1720 2nd Avenue South, Birmingham, AL, 35294, USA. ksaag@uabmc.edu.ORCID 0000-0001-6189-8078

Funding

Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RIZZO, MATTHEW · 2016 to 2025
$42.8M
Training Program in Rheumatic and Musculoskeletal Diseases ResearchT32AR069516 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI John D Mountz · 2016 to 2026
$2.6M
Ironwood Pharmaceuticals, Incorporated ESR-15-11Q77NIAMS NIH HHS T32 AR069516NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

objectiveTo examine the feasibility, preference, and satisfaction of an interactive voice response (IVR) system versus a customized smartphone application (StudyBuddy) to capture gout flares

methodsIn this 24-week prospective, randomized, crossover, open-label pilot study, 44 gout patients were randomized to IVR vs. StudyBuddy and were crossed over to the other technology after 12 weeks. Flares were reported via weekly (and later daily) scheduled StudyBuddy or IVR queries. Feasibility was ascertained via response rate to scheduled queries. At 12 and 24 weeks, participants completed preference/satisfaction surveys. Preference and satisfaction were assessed using dichotomous or ordinal questions. Sensitivity was assessed by the frequency of flare reporting with each approach.

resultsThirty-eight of 44 participants completed the study. Among completers, feasibility was similar for IVR (81%) and StudyBuddy (80%). Conversely, most (74%) preferred StudyBuddy. Measures of satisfaction (ease of use, preference over in-person clinic visits, and willingness for future use) were similar between the IVR and StudyBuddy; however, more participants deemed the StudyBuddy as convenient (95% vs. 73%, P = 0.01) and less disruptive (97% vs. 82%, P = 0.03). Although the per patient number of weeks in flare was not significantly different (mean 3.4 vs. 2.6 weeks/patient, P = 0.15), the StudyBuddy captured more of the total flare weeks (35%) than IVR (27%, P = 0.02).

conclusionA smartphone application and IVR demonstrated similar feasibility but overall sensitivity to capture gout flares and participant preference were greater for the smartphone application. Participant preference for the smartphone application appeared to relate to perceptions of greater convenience and lower disruption.

trial registrationNCT, NCT02855437 . Registered 4 August 2016.

Indexed as

SmartphoneCross-Over StudiesDisease ProgressionFeasibility StudiesFemaleFollow-Up StudiesGoutHumansMaleMiddle AgedPilot ProjectsProspective StudiesReproducibility of ResultsSkinSurveys and QuestionnairesGout flaresInteractive voice response systemSmartphone application

Identifiers

PMID31255174
PMCPMC6599289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.